Form 4: Pfizer Director Acquires Phantom Stock Units

Pfizer Inc. Director Shantanu Narayen acquired 1,962.323 phantom stock units as deferred compensation, increasing his beneficial ownership to 178,125.307 units.

Summary

• Shantanu Narayen, a Director of Pfizer Inc., acquired 1,962.323 phantom stock units.
• The transaction occurred on September 30, 2025.
• Each unit represents one phantom share of common stock, priced at $25.48.
• These units are deferred director's compensation, including dividend equivalents.
• The units will be settled in cash or common stock at the director's election following retirement from the Board.
• Following this transaction, Narayen beneficially owns 178,125.307 phantom stock units.

Sentiment

Score: 7

Explanation: The acquisition of phantom stock units by a director is generally a positive signal, indicating alignment of interests and a form of compensation tied to company performance. It's not a direct investment, but a deferred compensation mechanism.

Positives

• Director Shantanu Narayen increased his beneficial ownership in Pfizer Inc. through the acquisition of 1,962.323 phantom stock units.
• The acquisition represents deferred director's compensation, aligning the director's interests with long-term shareholder value.

Future Outlook

The phantom stock units represent deferred compensation that will be settled in cash or common stock at the director's election following retirement from the Board of Directors.

Industry Context

This filing is a standard disclosure of insider transactions, common across all publicly traded companies, and does not provide specific industry-related insights beyond the company's name (Pfizer Inc. in the pharmaceutical industry).

Stakeholder Impact

• Shareholders: The acquisition of phantom stock units by a director aligns their interests with long-term shareholder value, as the value of these units is tied to the company's stock performance.

Next Steps

• Settlement of phantom stock units in cash or common stock upon the director's retirement from the Board of Directors.

Key Dates

Keywords

Pfizer, PFE, Shantanu Narayen, Insider Trading, Form 4, Phantom Stock Units, Director Compensation, Beneficial Ownership